Infection types in severe liver failure with hepatitis B or E
Part of Digestive system clinical trials.
This study is looking at the types of infections that can occur in people with severe liver failure (when the liver stops working) who have hepatitis B or E. By identifying these infections, doctors hope to better treat and prevent complications in patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a long-term hepatitis B infection (positive for more than 6 months) or a current hepatitis E infection.
- Your jaundice (yellowing of skin and eyes) has been getting worse quickly, with a blood test showing very high bilirubin levels (more than 10 times the normal upper limit, or rising fast).
- You have a significant bleeding tendency, shown by a blood test result (prothrombin activity at 40% or below).
- You do not have severe liver inflammation caused by other viruses (like hepatitis A or C).
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the types of germs (bacteria or viruses) that cause infections in people who have cirrhosis from Hepatitis B. The goal is to learn which germs are common, so doctors can better treat or prevent such infections in the future.
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
Hear when a new Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.